This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John P. Blass, MD; R. A. Pieter Kark, MD; W. King Engel, MD

Arch Neurol. 1971;25(5):449-460.

Abstract
A boy with a hereditary defect of pyruvate decarboxylase has had intermittent ataxia, often with choreoathetosis, following fever or excitement, and lasting several days, but is clinically normal between attacks. There were excessive lipid droplets in his skeletal muscle. Blood, urine, and cerebrospinal fluid pyruvate levels were increased as were blood and urine alanine levels but blood lactate levels were rarely abnormal. Pyruvate levels tended to be higher during an attack, and then, more abnormal (as were the clinical signs) in the late afternoon. Dexamethazone (Decadron) relieved the attacks without affecting blood pyruvate. Thiamine had little effect although attack frequency declined after 19 months of treatment. This disorder, in which a constant metabolic defect predisposes to intermittent symptoms, may provide a model for understanding the relations between genetic and environmental factors in other diseases.

Author Affiliations
Los Angeles; Bethesda, Md

From the Medical Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Md (Drs. Kark and Engel), and the Mental Retardation Center, Neuropsychiatric Institute, UCLA School of Medicine, Los Angeles (Dr. Blass).

Footnotes
Accepted for publication May 25, 1971.

Reprint requests to Medical Neurology Branch, National Institute of Neurological Diseases and Stroke, Bethesda, Md 20014 (Dr. Engel).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical Review Article: Organic Acidurias: A Review. Part 1
Ozand and Gascon
J Child Neurol 1991;6:196-219.
ABSTRACT  

In Utero Central Nervous System Damage in Pyruvate Dehydrogenase Deficiency
Aleck et al.
Arch Neurol 1988;45:987-989.
ABSTRACT  

Spino-Cerebellar Degeneration With Polyneuropathy Associated With Ceroid Lipofuscinosis in One Family
Wisniewski et al.
J Child Neurol 1988;3:33-41.
ABSTRACT  

Pyruvate Decarboxylase Deficiency in Subacute Necrotizing Encephalomyelopathy
Evans
Arch Neurol 1981;38:515-519.
ABSTRACT  

Ophthalmoplegia-Plus: Its Occurrence With Periventricular Diffuse Low Density on Computed Tomography Scan
Okamoto et al.
Arch Neurol 1981;38:423-426.
ABSTRACT  

Paroxysmal Dystonia
DUNN
Arch Pediatr Adolesc Med 1981;135:381-382.
ABSTRACT  

Acetazolamide in the Treatment of Pyruvate Dysmetabolism Syndromes
Evans et al.
Arch Neurol 1978;35:302-305.
ABSTRACT  

Hepatitis-Associated Lipid Storage Myopathy
PATTEN et al.
ANN INTERN MED 1977;87:417-421.
ABSTRACT  

Experimental Thiamine Deficiency: Neuropathic and Mitochondrial Changes Induced in Rat Muscle
Kark et al.
Arch Neurol 1975;32:818-825.
ABSTRACT  

Absence of pyruvate decarboxylase activity in man: a cause of congenital lactic acidosis
Farrell et al.
Science 1975;187:1082-1084.
ABSTRACT  

Muscle Carnitine Deficiency: Association With Lipid Myopathy, Vacuolar Neuropathy, and Vacuolated Leukocytes
Markesbery et al.
Arch Neurol 1974;31:320-324.
ABSTRACT  

Subacute Necrotizing Encephalomyelopathy: Rapidly Fatal Course of Leigh Disease in a 5-year-old Child
Eisengart et al.
Arch Pediatr Adolesc Med 1974;127:730-732.
ABSTRACT  

Lipid Storage Myopathy Responsive to Prednisone
Engel and Siekert
Arch Neurol 1972;27:174-181.
ABSTRACT